Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
01
2022
accepted:
15
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
To review and compare the PON-1 arylesterase activity between coronary artery disease (CAD) and non-CAD patients. Data were obtained by searching MEDLINE and Scopus for all investigations published between January 1, 2000 and March 1, 2021 comparing PON-1 arylesterase activity between CAD and controls. Twenty studies, based on 5417 patients, met the inclusion criteria and were included in the analysis. A random effect model revealed that PON-1 arylesterase activity was significantly lower in the CAD group compared to controls (SMD = -0.587, 95%CI = -0.776 to -0.339, PON-1 activity is significantly lower in CAD patients, and those without DM presented a significantly higher PON-1 arylesterase activity.
Identifiants
pubmed: 35308142
doi: 10.1155/2022/4264314
pmc: PMC8930235
doi:
Substances chimiques
Carboxylic Ester Hydrolases
EC 3.1.1.-
arylesterase
EC 3.1.1.2
Aryldialkylphosphatase
EC 3.1.8.1
PON1 protein, human
EC 3.1.8.1
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4264314Subventions
Organisme : NIEHS NIH HHS
ID : P42 ES004696
Pays : United States
Informations de copyright
Copyright © 2022 Marco Zuin et al.
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Arch Cardiol Mex. 2016 Oct - Dec;86(4):350-357
pubmed: 27640339
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Med Sci Monit. 2009 Oct;15(10):RA209-219
pubmed: 19789524
J Atheroscler Thromb. 2002;9(3):133-8
pubmed: 12226554
Arq Bras Cardiol. 2003 Apr;80(4):379-95
pubmed: 12754559
Oncotarget. 2017 Mar 21;8(12):19443-19454
pubmed: 28038449
Oxid Med Cell Longev. 2015;2015:5136937
pubmed: 26697134
Atherosclerosis. 2008 Aug;199(2):408-14
pubmed: 18164014
Biochem Genet. 2021 Aug;59(4):919-939
pubmed: 33599870
Atherosclerosis. 2011 Feb;214(2):377-85
pubmed: 21146823
Coron Artery Dis. 2008 Dec;19(8):565-73
pubmed: 19005291
J Clin Neurol. 2014 Apr;10(2):140-7
pubmed: 24829600
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Br J Clin Pharmacol. 2008 Sep;66(3):366-74
pubmed: 18492126
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):854-60
pubmed: 15681296
J Clin Biochem Nutr. 2009 Nov;45(3):278-84
pubmed: 19902017
J Clin Diagn Res. 2013 Jul;7(7):1284-7
pubmed: 23998046
Atherosclerosis. 2019 Jan;280:7-13
pubmed: 30448568
Clin Biochem. 2002 May;35(3):197-203
pubmed: 12074827
Int J Vasc Med. 2016;2016:6312478
pubmed: 27213056
Clin Biochem. 2010 Apr;43(6):553-8
pubmed: 20026099
Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62
pubmed: 27238723
J Intern Med. 2004 Oct;256(4):308-15
pubmed: 15367173
Atherosclerosis. 2002 Jun;162(2):381-9
pubmed: 11996958
Drug Discov Ther. 2019;13(2):80-88
pubmed: 31080207
Atherosclerosis. 2016 Feb;245:143-54
pubmed: 26724525
FEBS Lett. 1998 Feb 13;423(1):57-60
pubmed: 9506841
Free Radic Biol Med. 2003 Mar 15;34(6):774-84
pubmed: 12633754
Diabetes. 2000 Aug;49(8):1390-3
pubmed: 10923642
FEBS Lett. 1991 Jul 29;286(1-2):152-4
pubmed: 1650712
Future Cardiol. 2021 Jan;17(1):119-126
pubmed: 32583675
Clin Biochem. 2006 Aug;39(8):821-5
pubmed: 16875684
Circulation. 2002 Jul 23;106(4):484-90
pubmed: 12135950
Cardiovasc Diabetol. 2015 May 13;14:52
pubmed: 25964115
Circulation. 2001 Jun 5;103(22):2705-10
pubmed: 11390341
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):328-34
pubmed: 12588779
Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1451-7
pubmed: 11557671
Heart Vessels. 2020 Jul;35(7):918-929
pubmed: 32034489
Curr Med Chem. 2020;27(7):1052-1080
pubmed: 31470773
Prog Lipid Res. 2015 Oct;60:50-73
pubmed: 26416579
J Atheroscler Thromb. 2000;7(3):152-8
pubmed: 11480456